-
1
-
-
84948807267
-
Checkpoint blockade for the treatment of advanced melanoma
-
Callahan MK, Flaherty CR, Postow MA. Checkpoint blockade for the treatment of advanced melanoma. Cancer Treat Res. 2016;167:231-250.
-
(2016)
Cancer Treat Res
, vol.167
, pp. 231-250
-
-
Callahan, M.K.1
Flaherty, C.R.2
Postow, M.A.3
-
2
-
-
84944937210
-
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
-
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
-
(2015)
N Engl J Med
, vol.373
, pp. 1627-1639
-
-
Borghaei, H.1
Paz-Ares, L.2
Horn, L.3
-
3
-
-
84946607195
-
Nivolumab versus everolimus in advanced renal-cell carcinoma
-
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-1813.
-
(2015)
N Engl J Med
, vol.373
, pp. 1803-1813
-
-
Motzer, R.J.1
Escudier, B.2
McDermott, D.F.3
-
4
-
-
84929481482
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
-
Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-2017.
-
(2015)
N Engl J Med
, vol.372
, pp. 2006-2017
-
-
Postow, M.A.1
Chesney, J.2
Pavlick, A.C.3
-
5
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
-
(2015)
N Engl J Med
, vol.373
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
-
6
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
-
Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'Day, S.3
-
7
-
-
33749319703
-
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
-
Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
-
(2006)
Science
, vol.313
, pp. 1960-1964
-
-
Galon, J.1
Costes, A.2
Sanchez-Cabo, F.3
-
8
-
-
77649193013
-
Immune infiltration in human tumors: A prognostic factor that should not be ignored
-
Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093-1102.
-
(2010)
Oncogene
, vol.29
, pp. 1093-1102
-
-
Pagès, F.1
Galon, J.2
Dieu-Nosjean, M.C.3
Tartour, E.4
Sautes-Fridman, C.5
Fridman, W.H.6
-
9
-
-
84920956732
-
PD-1 blockade induces responses by inhibiting adaptive immune resistance
-
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-571.
-
(2014)
Nature
, vol.515
, pp. 568-571
-
-
Tumeh, P.C.1
Harview, C.L.2
Yearley, J.H.3
-
10
-
-
84879104519
-
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors
-
Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73:3591-3603.
-
(2013)
Cancer Res
, vol.73
, pp. 3591-3603
-
-
Duraiswamy, J.1
Kaluza, K.M.2
Freeman, G.J.3
Coukos, G.4
-
11
-
-
77954042065
-
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine
-
Vosjan MJ, Perk LR, Visser GW, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-743.
-
(2010)
Nat Protoc
, vol.5
, pp. 739-743
-
-
Vosjan, M.J.1
Perk, L.R.2
Visser, G.W.3
-
12
-
-
84950117835
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial
-
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-1550.
-
(2016)
Lancet
, vol.387
, pp. 1540-1550
-
-
Herbst, R.S.1
Baas, P.2
Kim, D.W.3
-
13
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
14
-
-
84874830056
-
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types
-
Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res. 2013;19:1009-1020.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 1009-1020
-
-
Ascierto, P.A.1
Kalos, M.2
Schaer, D.A.3
Callahan, M.K.4
Wolchok, J.D.5
-
15
-
-
84861194756
-
The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer
-
Roxburgh CS, McMillan D. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev. 2012;38:451-466.
-
(2012)
Cancer Treat Rev
, vol.38
, pp. 451-466
-
-
Roxburgh, C.S.1
McMillan, D.2
-
16
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
-
(2015)
N Engl J Med
, vol.372
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
-
17
-
-
84928761118
-
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
-
Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-128.
-
(2015)
Science
, vol.348
, pp. 124-128
-
-
Rizvi, N.A.1
Hellmann, M.D.2
Snyder, A.3
-
18
-
-
84948418552
-
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
-
Maute RL, Gordon SR, Mayer AT, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA. 2015;112:E6506-E6514.
-
(2015)
Proc Natl Acad Sci USA
, vol.112
, pp. E6506-E6514
-
-
Maute, R.L.1
Gordon, S.R.2
Mayer, A.T.3
-
19
-
-
84958953141
-
An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy
-
Tavaré R, Escuin-Ordinas H, Mok S, et al. An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 2016;76:73-82.
-
(2016)
Cancer Res
, vol.76
, pp. 73-82
-
-
Tavaré, R.1
Escuin-Ordinas, H.2
Mok, S.3
|